Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue
Vahid Heravi Shargh, Jeni Luckett, Kaouthar Bouzinab, Stephen J. Paisey, Lyudmila Turyanska, William Singleton, Stephen P. Lowis, Pavel Gershkovich, Tracey D. Bradshaw, Malcolm F. G. Stevens, Alison Bienemann, Beth Coyle
Abstract
Zr radionuclide in terms of localized distribution kinetics and retention within the brain parenchyma. Overall, both NP formulations of N3P represent promising approaches for treatment of TMZ-resistant DIPG and merit the next phase of preclinical evaluation.
Topics & Concepts
TemozolomideIn vivoMaterials scienceIC50PharmacologyPropargylPharmacokineticsCancer researchBiophysicsIn vitroGliomaMolecular biologyChemistryMedicineBiochemistryBiologyCatalysisBiotechnologyGlioma Diagnosis and TreatmentNanoparticle-Based Drug DeliveryMicroRNA in disease regulation